Humanized Anti-GPC-1 Antibody
AssigneeIwate Medical University
InventorsTetsuji Naka, Satoshi Serada
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a humanized antibody that specifically binds to Glypican-1 (GPC-1), and also provides technologies, methods, medicines, and the like related to the humanized antibody. In one aspect, the present disclosure provides a humanized anti-GPC-1 monoclonal antibody that has a high affinity for GPC-1 and has high internalization activity in GPC-1-positive cells. In another aspect, the present disclosure also provides a composition for preventing or treating Glypican-1-positive cancer that includes a complex of a humanized anti-GPC-1 monoclonal antibody and a medicine having cytotoxic activity.
Claims20
An antibody-drug conjugate comprising a humanized anti-GPC-1 antibody or an antigen-binding fragment thereof, and a medicine having cytotoxic activity, the humanized antibody or the antigen-binding fragment thereof comprising:
- heavy-chain CDRs 1 to 3 comprising amino acid sequences set forth in SEQ ID NOs:
- 28 to 30, respectively, and
- light-chain CDRs 1 to 3 comprising amino acid sequences set forth in SEQ ID NOs:
- 31 to 33, respectively.
Dependencies are inferred from the claim text.